Targeting CD38/ ADP-ribosyl cyclase as a novel therapeutic strategy for identification of three potent agonists for leukopenia treatment
Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved..
Leukopenia is the most common side effect of chemotherapy and radiotherapy. It potentially deteriorates into a life-threatening complication in cancer patients. Despite several agents being approved for clinical administration, there are still high incidences of pathogen-related disease due to a lack of functional immune cells. ADP-ribosyl cyclase of CD38 displays a regulatory effect on leukopoiesis and the immune system. To explore whether the ADP-ribosyl cyclase was a potential therapeutic target of leukopenia. We established a drug screening model based on an ADP-ribosyl cyclase-based pharmacophore generation algorithm and discovered three novel ADP-ribosyl cyclase agonists: ziyuglycoside II (ZGSII), brevifolincarboxylic acid (BA), and 3,4-dihydroxy-5-methoxybenzoic acid (DMA). Then, in vitro experiments demonstrated that these three natural compounds significantly promoted myeloid differentiation and antibacterial activity in NB4 cells. In vivo, experiments confirmed that the compounds also stimulated the recovery of leukocytes in irradiation-induced mice and zebrafish. The mechanism was investigated by network pharmacology, and the top 12 biological processes and the top 20 signaling pathways were obtained by intersecting target genes among ZGSII, BA, DMA, and leukopenia. The potential signaling molecules involved were further explored through experiments. Finally, the ADP-ribosyl cyclase agonists (ZGSII, BA, and DMA) has been found to regenerate microbicidal myeloid cells to effectively ameliorate leukopenia-associated infection by activating CD38/ADP-ribosyl cyclase-Ca2+-NFAT. In summary, this study constructs a drug screening model to discover active compounds against leukopenia, reveals the critical roles of ADP-ribosyl cyclase in promoting myeloid differentiation and the immune response, and provides a promising strategy for the treatment of radiation-induced leukopenia.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:200 |
|---|---|
| Enthalten in: |
Pharmacological research - 200(2024) vom: 24. Feb., Seite 107068 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Liu, Yuanzhi [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 14.02.2024 Date Revised 14.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.phrs.2024.107068 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367234149 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367234149 | ||
| 003 | DE-627 | ||
| 005 | 20240214233121.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240118s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.phrs.2024.107068 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1293.xml |
| 035 | |a (DE-627)NLM367234149 | ||
| 035 | |a (NLM)38232908 | ||
| 035 | |a (PII)S1043-6618(24)00012-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Liu, Yuanzhi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Targeting CD38/ ADP-ribosyl cyclase as a novel therapeutic strategy for identification of three potent agonists for leukopenia treatment |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.02.2024 | ||
| 500 | |a Date Revised 14.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a Leukopenia is the most common side effect of chemotherapy and radiotherapy. It potentially deteriorates into a life-threatening complication in cancer patients. Despite several agents being approved for clinical administration, there are still high incidences of pathogen-related disease due to a lack of functional immune cells. ADP-ribosyl cyclase of CD38 displays a regulatory effect on leukopoiesis and the immune system. To explore whether the ADP-ribosyl cyclase was a potential therapeutic target of leukopenia. We established a drug screening model based on an ADP-ribosyl cyclase-based pharmacophore generation algorithm and discovered three novel ADP-ribosyl cyclase agonists: ziyuglycoside II (ZGSII), brevifolincarboxylic acid (BA), and 3,4-dihydroxy-5-methoxybenzoic acid (DMA). Then, in vitro experiments demonstrated that these three natural compounds significantly promoted myeloid differentiation and antibacterial activity in NB4 cells. In vivo, experiments confirmed that the compounds also stimulated the recovery of leukocytes in irradiation-induced mice and zebrafish. The mechanism was investigated by network pharmacology, and the top 12 biological processes and the top 20 signaling pathways were obtained by intersecting target genes among ZGSII, BA, DMA, and leukopenia. The potential signaling molecules involved were further explored through experiments. Finally, the ADP-ribosyl cyclase agonists (ZGSII, BA, and DMA) has been found to regenerate microbicidal myeloid cells to effectively ameliorate leukopenia-associated infection by activating CD38/ADP-ribosyl cyclase-Ca2+-NFAT. In summary, this study constructs a drug screening model to discover active compounds against leukopenia, reveals the critical roles of ADP-ribosyl cyclase in promoting myeloid differentiation and the immune response, and provides a promising strategy for the treatment of radiation-induced leukopenia | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a (-)-gallocatechin (PubChem CID: 9882981) | |
| 650 | 4 | |a 3,4-dihydroxy-5-methoxybenzoic acid | |
| 650 | 4 | |a 3,4-dihydroxy-5-methoxybenzoic acid (PubChem CID: 19829) | |
| 650 | 4 | |a ADP-ribosyl cyclase | |
| 650 | 4 | |a Brevifolincarboxylic acid | |
| 650 | 4 | |a Brevifolincarboxylic acid (PubChem CID: 9838995) | |
| 650 | 4 | |a Citric acid (PubChem CID: 311) | |
| 650 | 4 | |a Leukopenia | |
| 650 | 4 | |a Oleanolic acid (PubChem CID: 10494) | |
| 650 | 4 | |a Procyanidin B3 (PubChem CID: 146798) | |
| 650 | 4 | |a Syringic acid (PubChem CID: 10742) | |
| 650 | 4 | |a Virtual screening | |
| 650 | 4 | |a Ziyuglycoside II | |
| 650 | 4 | |a Ziyuglycoside II (PubChem CID: 15984080) | |
| 650 | 7 | |a ADP-ribosyl Cyclase |2 NLM | |
| 650 | 7 | |a EC 3.2.2.5 |2 NLM | |
| 650 | 7 | |a ADP-ribosyl Cyclase 1 |2 NLM | |
| 650 | 7 | |a EC 3.2.2.6 |2 NLM | |
| 650 | 7 | |a Antigens, CD |2 NLM | |
| 650 | 7 | |a Antigens, Differentiation |2 NLM | |
| 650 | 7 | |a Membrane Glycoproteins |2 NLM | |
| 700 | 1 | |a Zhang, Linwei |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Long |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Xiaoqin |e verfasserin |4 aut | |
| 700 | 1 | |a Wan, Shengli |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Qianqian |e verfasserin |4 aut | |
| 700 | 1 | |a Ran, Mei |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Hongping |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Chiampanichayakul, Sawitree |e verfasserin |4 aut | |
| 700 | 1 | |a Tima, Singkome |e verfasserin |4 aut | |
| 700 | 1 | |a Anuchapreeda, Songyot |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Jianming |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmacological research |d 1992 |g 200(2024) vom: 24. Feb., Seite 107068 |w (DE-627)NLM012597384 |x 1096-1186 |7 nnns |
| 773 | 1 | 8 | |g volume:200 |g year:2024 |g day:24 |g month:02 |g pages:107068 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.phrs.2024.107068 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 200 |j 2024 |b 24 |c 02 |h 107068 | ||